Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Buy ...

Deutsche Bank initiated coverage of Denali Therapeutics (DNLI) with a Buy rating and $31 price target Maximize Your Portfolio with Data Driven ...

After winning a breakthrough therapy designation for its Hunter syndrome enzyme replacement therapy, Denali Therapeutics is ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today and set a price target of ...

Deutsche Bank (ETR:DBKGn) initiated coverage on Denali Therapeutics Inc. (NASDAQ: NASDAQ:DNLI) with a Buy rating and set a price target of $31.00. The new assessment comes as Denali's shares are seen ...

A Denali Therapeutics drug for the rare enzyme deficiency Hunter syndrome is still in pivotal testing, but the company has guidance from the FDA on a pathway to get this therapy to the market sooner.

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging ...

Denali Therapeutics (NASDAQ:DNLI – Free Report) had its target price trimmed by The Goldman Sachs Group from $45.00 to $40.00 in a research report sent to investors on Tuesday morning,Benzinga reports ...